Keywords: Amgen, Xencor, Autoimmune diseases, XmAb5871, Licensing

Amgen and Xencor ink $500 million option pact to co-develop novel antibody for autoimmune diseases

Article | 07 January 2011

Print This

US biotech major Amgen (Nasdaq: AMGN) and privately-held Xencor have signed a collaboration to develop XmAb n5871, an Fc- engineered ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in